IRCT20150815023620N8 IRCT 2018-07-08 Tehran Azad University, Dentistry Faculty Dexmedetomidine in success of nerve block Evaluation of effect of adding Dexmedetomidine to Lidocaine in success of inferior alveolar nerve block in patients with asymptomatic irreversible pulpitis 2017-11-22 anticipated 50 Complete https://irct.ir/trial/20128 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Method of randomization: Randomized block method with equal-sized group. Unit of randomization: Individual. Tools: Statistical software excel version 10. Allocation concealment: Coding of samples and sealed envelopes placement, Blinding description: The study is double blinded; The operator and patients are blinded since the operator(endodontist) receives a sealed envelope containing drugs with code break system. Patients are examined while are aware of identity of study and declaration of consent from being involved in study without being informed of the content of drug. The evaluator measures and records the result of Visual Analog Scale test and Electric Pulp Test. 0 (exploratory trials) asymptomatic irreversible pulpitis. Intervention 1: intervention group:Dexmedetomidine 0.5µ\kg (0.4ml) + Lidocaine 1.55%(1.4ml) Dexmedetomidine is manufactured by Hospira. Each patient in Intervention group recieves an Inferior Alveolar Nerve Block injection containing described composition. Intervention 2: Control group: Lidocaine 2% (1.4ml) + Normal saline(0.4ml). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information